Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

Deltex raise 1,000,000 in a share placing.

I never have any problem with fund raising if it's for the right reasons, although as this was a placing, us poor PI's never got a look in.
But hopefully this could indicate things are about to start moving and a right issue would be both time consuming as well as more expensive, so if that extra bit of cash means a minute dilution of my holdings them so be it.
Reading between the lines, could this mean that there are several formal inquiries re contracts and supply taking place.
One can but hope.

Deltex will have to show that they can deal with any reasonable responses to the NICE papers.

Patience still required, but with the NICE recommendations the clock is definitely ticking.

Greek.

I am trying to be patient honestly.

The NHS have known of the proven benefits of the CardioQ system for many months if not years, they have also had the NICE final report for 6 weeks.
OK 6 weeks is not that long, although it feels like longer, also we don't know what is happening behind the scenes so to speak.
There may be many moves to procure the CardioQ system as a general uptake in the NHS, but as we are not privy to such information, we can only guess and hope.

I will as previously stated give it till the end of this year, before deciding to stay with this share or jump ship.

I appreciate this is not the time to make waves, especially as we know Deltex are busy gearing up production scales, but if contracts don't start to filter though within the next few months, surely it will be the time for the Deltex Management to think about publicity to shame the NHS Trusts into action.

As we all know the CardioQ saves lives and money (average saving per patient of 1,100 per hospital stay, this represents a potential 1 billion annualised saving), so the very slow take up of the system is a national NHS disgrace.

I am sure that all of those who have Deltex shares believe that the none institutional take up of the CardioQ is nothing more than verging on farcical.

If within a few months, procrastination still rules, I intend to e-mail Ewan Phillips to see what action is intended if any, to bring this to the attention of the many health and welfare reporters in the media.

With reference to my post of last Monday.
Patience is wearing very thin.
Whilst I appreciate that Deltex are gearing up to increase production, surely this should have no impact on the delay of gaining further contracts.
There is nothing to stop contracts being signed with the proviso that delivery of the product is set over a certain timescale.

As I compile this post, yet another 7am comes and goes without a RNS.
Will we be looking at another week, then another month.
If no RNS is released by next Monday, I intend to E-Mail Ewan Phillips.
I am not prepared to wait any longer.
We need answers!

I intend to ask/suggest that this further procrastination by the NHS Trusts are bought to the attention of the media.

I feel that certain newspapers should have this blatant waste of money by the health service managers bought to their attention, and therefor the publics.

Perhaps programme makers such as Dispatchers/Panorama and the like would be interested.

On the 7th October last year I sent an e-mail to Mr Phillips, receiving a reply the same day.

That e-mail was for clarification in several areas of progress. It was sent as a request 'from a small group of investors'.

The reply was as forthcoming as possible allowing for both LSE disclosure rules and company confidentiality.

I would also like the intended e-mail to be forwarded as a request from more than myself.

Please feel free to endorse the 'idea' of the intended contact by voting up this post.

Prior to contacting Mr Phillips I will post the content of proposed contact on this thread in order to allow others to comment on both the content and also to propose any amendments.

Any reply would of course be copied back here.

The softly, softly approach has been tried for too long.
After over 70 positive test results and now a full recommendation by NICE, there is no way that any further delay on take up can be justified by the NHS.

Deltex should now be in a position of being overwelmed by potential customers. They should no longer be having to go round trying to perswade people to by!
Potential buyers should be knocking on 'Deltex's door'!

If no-one is listening, we need to knock louder!

Strange.....Market is well down, Deltex daily volume about average or slightly up, all deals are down as sells and yet contrary to what usually happens when all these things occur together, Deltex sp is static.

Could it be that I am just hoping for that bit of good news, being round the corner.

Just can't read this share.

Over the last 3 days and todays early morning trades, all were reported as sells, except for 3 that were unknown.
Total sold, 1,280,000, not including the few sells on Plus.
Not a massive volume or value, but normally these sells would have triggered further drops in the sp, especially as the market in general was also down over the same period, with many AIM shares taking big knocks.
Not trying to read anything into this, but I do find it hard to believe that there have been 'No recorded buys' among the 50 or so trades.

I always thought that trying to understand women was difficult, but compared to understanding the workings of the stock market, women are an open book!

Still only sells, till the mm's upped both the bid and offer.
This resulted in a couple of buys, then tailed off, so they upped both again.
Anyone else feel they have a biggish order to fill, or am I yet again, reading something into nothing?

It's so quiet you could hear a contract being signed, that is if there were any.
Still looking toward to the trading statement without much confidence.
Many say I am inpatient, and they may be right, but having held Deltex shares for many a year, I felt that with the many positive trials, coupled with the multiple positive analytical reviews, finalising with the NICE recommendations I had ever right to be more positive than ever before.
Then what happens. Have Deltex started to bang the drum?. They may be doing just that, but if they are it must be so gently that nothing is appearing on my radar.
Surely if they can't make 'noticeable' inroads into the NHS at this stage then what chance do they have.
Austerity measures are soon coming regarding NHS funding, so now must be the time when NHS Trusts are looking at saving money.
Also it is not just this saving of money that is important but they must be seen to be saving said money.
Publicity has to be the key. Is this angle being looked at by Deltex!
The NHS is always being knocked by bad publicity, so some good publicity such as NHS looks to save millions by using the CardioQ, must be a way forward.
We should be seeing competition (because thats what they are in) between NHS Trusts regarding many aspects of cost savings, the CardioQ included.
Of course outside the medical world, the only laymen that have heard of the CardioQ never mind knowing it's benefits is limited to the investors.
that would change, if the publicity was out there.

Of course the bigger market is outside the NHS, but I feel that until the home market increases those outside markets will ask the obvious question, IE if it's so good how come etc, etc.

I am beginning to feel that if Deltex made life jackets, they would struggle to sell them to passengers of the titanic.

Well as already said, the trading statement is my catalyst, as I will not be going down if the ship starts to sink, or even if it becomes like the slow boat to China.

I appreciate my post is very pessimistic, but that's just how I feel.

Greek.

From a RHP.

A free tip, so that is why I have put the link.

Quote....The CardioQ, with its terrific contribution to patient recovery and NHS efficiency has been around for years. But only now when the pressure is really on to save money is the NHS grasping the nettle.

My comment...Well if they have grasped it, I can't see much sign yet.

Do RHP know something we don't, or is is just a repeat article for just something to say.

http://info.redhotpennyshares.co.uk/deltex_medical_just_hit_the_jackpot?gclid=CKqpjcvh-KkCFUFC4QodOGvaXw&T=1310369178&JTID=177168225&OGID=52&network=GAW

Things are looking good, but are they good enough.
I expected to see a few good solid contracts, not an agreement to implementation.
Surely the 200 plus medical papers along with the NICE recommendations should have produced more than this.
So I have decided to meet this Trading Statement halfway, and have sold half my holdings in Deltex.

Finally out.

Although still feeling Deltex will get there, albeit very slowly, I also feel that with the present or more importantly the near future economic situation mainly lead by the EU and the USA, the sp for this company will continue to drop following the general market direction.
Re the trading statement, in the UK it looks as if 400k and a 27% increase in sales has been made in the last 6 months, and yes the NICE result only accounts for half of that period.
But I feel that if they had had a better marketing strategy in place a couple of years ago, then a 27% increase in sales on what would have been far higher sales pre this increase would have resulted in an amount far exceeding a paltry 400k.
It is far easier to increase sales by a higher percentage when sales are low than it is to attain that same percentage increase on a larger stating volume.

So I'm now fully out of Deltex.
My final view is that, if the situation starts to look far better for the company, there will be a few chances to get back in around todays price, if I choose.

Obviously once out, it would be annoying to see the sp rise, but if it goes in the other direction, I am not one of those who will com back and gloat.

So I wish all still in and posting the best of luck.

I have enjoyed the ride, frustrating as it has been, and thanks to all who have contributed over the years to make his thread one of the best, and one of the few grown-up threads on MoneyAm.

I will look in now and then over the next few months.

Regards to all.
Pond.

I saw the RNS this morning and thought I would look in again expecting to see a few posts from the regulars, but no.
In fact the last poster on here was me over 6 weeks ago.
This goes to show the falling interest in Deltex as a company.

The results on the whole look mixed, with the positives of the growth figures, especially in the UK, negated by the increase in the loss figures.

I read an article in yesterdays Daily Telegraph, re the power of contacts that some companies have.

It mentioned Glaxo and how they can get products into any hospital within 24 hours (mainly of course due to their world wide distribution network), and no doubt there are many other, Smith and Nephew, Shire, etc.

As said before, Deltex need a company of that magnitude (or thereabouts) as a partner.

So I give Deltex a C pass for their efforts, with a could do better final remark.

I still look at the product and think, 'Why is this still not being looked at as a must have technology in all hospitals, world wide'.

I did note that inventory volume has been vastly increased, so hopefully this could mean that they know something we don't.

I won't post again for a while, as I appreciate any post from a none holder can be annoying.

Also I feel I have done the partnership issue to death and there is nothing new to say.

Good luck to all holders.

Greek.

greekman,

If you sell here, where would you put the money with better chances of growth? The reason that the Deltex share price is going down is that the whole market is a festering stinking load of pants. It's not Deltex's fault. I've been a shareholder here since early 2005 and I'm not selling. I know people who have been investors for even longer. I have watched the revenues going up year on year, with or without NICE recommendation. Even in 2008, the year when the whole stock market went to Hell in a hand-cart, when everyone was screaming in pain, Deltex's revenues increased. The ship sails on, through the storm.

This year the stock market is again going down the toilet, and Deltex sails on, with revenues up.



Why is there only one monopolies' commission?
What if there were no hypothetical questions?

I never use cliches. I avoid them like the plague.

I haven't started procrastinating yet!

I don't make predictions and I never will.


You know anarchists have their symbol which is like a capital A with another line in it? The question is...
IF THEY'RE ANARCHISTS, WHY DO THEY ALL USE THE SAME SYMBOL???


I know a man who was so old, he went on an internet dating web site and they said he should use THE CARBON DATING web site.


Zippy says: when you get your PhD will you be able to work at MACDONALDS?

Hospital accountants don't look at saving money like the Public - it appears to be a no-brainer, like locking up all burglars . . but then the Police would have nowt to do.

So if a technology can save money the Hospital buys them, Hospital purchases go up. Accountants notice this - the Purchase Ledger say so.
If the hospital treats more patients, and they have fewer complications, no money changes hands . . . Accountants don't see thsi, but the Purchases has gone up . . . so they must try to keep them down, with delays, order-countersign, reorganising the Buyers and so on.
Purchases continue to rise, so Accountants stem the flow of Purchases, at least for 6-months - Accountants happy.

-and don't kid ourselves when selling to the NHS the price is Low! So don't expect any huge profits, just yet.

Whoopee! We're saved! We're saved! We're saved!

After being out for many months, finally back in as with watching and waiting I now feel that Deltex are just about to break through from 'all the talk' which I am not blaming the company for, to action.

Whilst still feeling that Deltex should have gone down the big brother partnering route, which would I feel have put them about a couple of years ahead of where they are now, I do think the tide has finally turned.

Greek.

From a RNS 5 March 2012

Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring ("ODM"), announces that the Department of Health's Innovative Technology Adoption Procurement Programme ("ITAPP") has selected intra-operative fluid monitoring as one of three technologies for wide adoption by the NHS in England.

From a RNS 2 days later.

Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring ("ODM"), announces that, following a tender process, it is one of the companies selected to sell cardiac output monitoring equipment to the NHS in England through NHS Supply Chain under a framework agreement that commences this week.

From an interview with Ewan Philips on 23rd July 2012, re the Nice and NHS implementation plan (mentioned by Festering Heaps post of same date)

Our best guess is that the implementation plan will be published at some point over the summer – the delays seem to have come mostly from the NHS sorting out the rules for the financial penalties (I do like that bit) they are planning for slow and non-adopters.

Momentum is growing behind Deltex Medical’s (LON:DEMG) lead product, a budget easing surgical aid, as it moves closer to a full roll out into Britain’s National Health Service.

As summer is from 21 June till 21 Sept, it surely can't be long now.

When I bought back in on 24th July, I did so expecting the implementation plan to be late, after all this is the NHS we are talking about, but I am still expecting at least a few orders to start trickling through in the next couple of weeks.

I also noted that the sp moved very little after the 2 what looked like blockbusting RNS's, but as ever that was because we have been down the 'promises' road many times before, but I strongly believe that 'if' the implementation plan does get moving, it will be those firm orders that the investors can't ignore, so the sp will finally start to DO SOMETHING.

With all the evidence of lives saved, time in hospitals reduced, lower re-admissions plus of course money saved, it beggars belief how the NHS managers have to be cajoled into doing something which is a no brainer.

Of course these same thumb in mouth lot who run the NHS trusts, will no doubt pay themselves the usual 'bonuses'.

Deltex Medical gaining ‘real traction’ despite NHS hold-up, says CEO
2:19 pm by Jamie Nimmo Deltex's Cardio-Q device has the potential to create huge savings
Deltex Medical (LON:DEMG) continues to make headway despite delays to the NHS roll-out of its oesophageal Doppler monitor, according to its CEO Ewan Phillips.

Last December, the government pledged to launch a number of health initiatives, one of which included fully implementing Deltex’s device, which safely monitors a patient’s blood flow during surgery using a probe inserted into the oesophagus.

It has the potential to create huge savings – £1,100 per patient to be more precise – as they recover more quickly from surgery, have fewer complications and therefore spend less time in hospital.

However, its launch has seen a number of delays, which did not come as a complete surprise to the company’s chief executive.

He said such hold-ups are not uncommon, but expects the initiative – expected shortly – will help the company cement its position as the market leader.

“It will be a really good trigger – if not a silver bullet, a sort of bronze bullet if you like,” Phillips told Proactive Investors.

“It ought to put us on a sustainable, even faster growth rate than we’re already on.

“But the business is feeling likes it’s gaining real traction in lots of places and growing quite nicely without that.”

Deltex saw sales rise 7 per cent to £3.2 mln in the first half of the year, helped by a strong demand for its fluid management system CardioQ-ODM, even without the NHS initiative.

The company added that sales had been “satisfactory” since the end of June, both in the UK and overseas in its half-year results out last week.

Phillips was quick to point out that the company always performs better in the second half of the year.

He reckons France, Scandinavia and Canada have the best prospects after the UK – which is the company’s core market – and are starting to move into an accelerated phase.

The work done in Canada, for example, was going well a year ago, but the business was still tiny there.

“Because it’s medical technology, stunningly well doesn’t mean a new product launched by Apple, but it’s pretty good,” Phillips added.

“Fingers crossed, Canada could go from nowhere to very exciting in a two to three-year period.”

As for the US, some might ask why the company is focusing on the UK and not the more lucrative American health market.

Phillips explains that the market penetration across the Atlantic is “very small”, especially given the tough year that the sector endured last year.

“The US last year was horrible for all med-tech companies; the whole hospital system struggled, with falls in volume.

“So our business – which had been growing quite steadily – hit a decline in the middle of last year and we felt by last November there were signs it was recovering,” he added.

“So we finished catching up around April this year and July and August came through quite nicely and we’re on a pretty good track.

“It’s all underpinned by proper, increased, regular usage in good quality accounts where we’ve done the groundwork, so we’re feeling pretty confident on that.

“At the moment, we don’t think it’s ready yet for the roll-out but we’re trying to do the work which will get it ready for the roll-out,” said Phillips.

“It takes time but things can move pretty fast in the States so it’s a case of watching, keeping our ear to the ground and finger on the pulse.”

Robin Campbell, an analyst at Merchant Securities, reckons the growth story looks encouraging.

“You’ve got to look at the monitors, the probes, the placements and look at the razor-blade model they hope to develop there and that all translates into growth,” he said.

Campbell also highlighted the possibility of a bigger player coming in and buying out the company.

“I can see someone coming in who wants to use the technology as part of their own portfolio and take over the small footprint that Deltex has put together.”

The great thing about medical technology is that these are long-term, recurring revenue streams; the difficulty is cracking the market in the first place, Phillip says.

And he believes the company is grinding down these barriers to entry and now finds itself “within touching distance” of an accelerated growth phase.

“The key thing we want to do is keep that probe growth coming in each of the UK, Europe and the US,” Phillips added.

“On top of that, we want to start to see ideally the UK first then other countries start to accelerate off that solid growth into something, if not spectacular, then something quite a bit more quickly.”

Deltex then is certainly one to keep a finger on the pulse of.

UPDATE: Deltex Medical sees "step change" as NHS targets big increase in fluids monitoring
7:29 am by Philip Whiterow Deltex says its CardioQ-ODM oesophageal Doppler monitor is “by some way the market leading fluid management monitor in surgery in the region" ---adds audio interview---

Deltex Medical (LON:DEMG) yesterday hailed as a “step change” a new NHS target for a big increase in patients in the south of England using fluid monitoring systems.

The move by the NHS follows a series of health initiatives launched by the government at the end of last year.

One of these was to implement fully "ODM or similar fluid management monitoring technologies" across the health service.

Deltex said its CardioQ-ODM oesophageal Doppler monitor is “by some way the market leading fluid management monitor in surgery in the region".

The targets just announced are for 150 patients per 100,000 in the south of England to be treated with fluid management systems by February and March of next year.

The target rises to 200 patients per 100,000 in the NHS financial year starting 1 April 2013; to 250 patients per 100,000 in the NHS financial year starting 1 April 2014 and to 400 patients per 100,000 in the NHS financial year starting 1 April 2015.

With the population in the region estimated at 13 mln, that would amount to about 54,000 patients per year on fluid management systems by 2015/16.






Ewan Phillips, Deltex Medical's chief executive, said: "Successful implementation of the NHS South of England plan will cause a step change in the market for intra-operative fluid management monitoring in the region in the next two and a half years, with clear potential for either faster or further growth to address the remaining three-quarters of patients where NICE already recommend CardioQ-ODM usage.

In the 2011, CardioQ-ODM was used during surgery on 50 patients a year per 100,000 of population in region covered by the new targets.

The device uses a probe inserted into the oesophagus to monitor a patient’s blood flow during surgery.

It has the potential to save £1,100 per patient treated as they recover more quickly from surgery, have fewer complications and therefore spend less time in hospital.

"CardioQ-ODM has a strong market leadership position in the NHS, is the most widely applicable technology available for major surgery, is the only technology recommended by NICE and is the only technology with an evidence base that shows both improved outcomes for patients and reduced lengths of hospital stay which are the benefits being pursued by the NHS," Phillips added.

I'm beginning to wonder if Deltex do have a viable product that will sell.
And it's sales that are by far the most important aspect of any product.
Just had a look at the 10 year chart, which shows that the sp was higher in 2004 (yes, nearly 9 years ago) than it is today.
Please Deltex, open your eyes and get a door opening partner in!